The most likely antiproliferative mechanism of metformin was reportedly associated with its ability to activate AMPK and LKB1, which inhibits the mechanistic target of rapamycin (mTOR) (a commonly dysregulated pathway in cancer) and consequently inhibit protein synthesis and cell proliferation [23]. This evidence concerns the gene MTOR and cancer.